Colorectal cancer (metastatic) - bevacizumab (TA212)
Fast, easy summary view of NICE guidance on 'colorectal cancer'
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
NICE does not recommend bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for people with metastatic colorectal cancer.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine does not provide enough benefit to patients to justify its high costs, and did not qualify for special consideration, so NICE did not recommend it.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: colorectal cancer
This page was last updated: 15 July 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA212 Bevacizumab ar y cyd ag oxaliplatin a naill ai fluorouracil ac asid ffolinig neu capecitabine ar gyfer canser metastatig y colon a'r rhefr: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.